Annual Report Menu

A Message From the President

DAVID PORTER, MD
ASTCT President - 2025

2025 Accomplishments

Icons_25Accomplishments_01
Developed a 2026-2028 strategic plan and a refresh of our mission and vision.
Icons_25Accomplishments_02
Advocated on the Hill for patient access and funding for research.
Icons_25Accomplishments_03
Delivered a refreshed user experience in the Practice Guidelines app.
Icons_25Accomplishments_04
Published a new HCT Coverage & Reimbursement Guide, in collaboration with NMDP℠.
Icons_25Accomplishments_05
Welcomed a record number of attendees to the 2025 Tandem Meetings.
Icons_25Accomplishments_06
Held 34 webinars for the HCT and cell therapy community.
Icons_25Accomplishments_07
Hosted seven meetings to bring together multidisciplinary professionals in the field.
Icons_25Accomplishments_08
Hosted a joint Solid Tumor Summit with SITC and produced a summary manuscript that will be published in Transplantation and Cellular Therapy in early 2026.
Icons_25Accomplishments_09
ASTCT’s 80/20 Committee’s efforts in removing REMS were acknowledged by the FDA.
Icons_25Accomplishments_10
Provided $700,000 of funding to support 7 young investigators’ research.
Icons_25Accomplishments_11
Established an MOU with the Pakistani Blood and Marrow Transplant Group and Alliance for Regenerative Medicine.
Icons_25Accomplishments_12
Distributed the first comprehensive HCT/CT Center Staffing Survey and shared results with all responding institutions.

Membership Report

ASTCT members span the entire field of HCT and cellular therapy — from basic science research to direct patient care. ASTCT offers a variety of membership types, including affiliate, associate, emeritus, in-training, international and institutional.

Visit our membership page to view benefits and learn more about our membership types.

 

2025 Membership

Member
1,752
Affiliate Member
1,137
Associate Member
62
In-Training Member
458
Institutional Affiliate Member
336
International Member
211
Emeritus Member
33
Total
3,989
 
Membership_2025

Member Region

North America
3,424
Asia Pacific
155
Europe, Middle East, Africa
135
Latin America
61
 
Member_Region

Membership Tenure

0-2 years:
2,672
3-5 years:
577
6-10 years:
336
11-15 years:
167
16-20 years:
122
 
Membership_Tenure

2025 ASTCT Board of Directors

Executive Committee

David Porter, MD
2025 President
University of Pennsylvania
Margaret MacMillan, MD, MSc, FRCPC
President Elect
University of Minnesota
Corey Cutler, MD, MPH
Immediate Past President
Dana-Farber Cancer Institute
Richard Maziarz, MD
Vice President
Oregon Health and Science University
Mehdi Hamadani, MD
Secretary
Medical College of Wisconsin
Eneida Nemecek, MD, MS, MBA
Treasurer
Oregon Health & Science University

SIG and Committee Accomplishments

SIG and volunteer committees are integral to developing education and guiding the future of the society. Below are some notable SIG and Committee accomplishments in 2025.


Committee Accomplishments

Committee on Awards
  • Awarded seven young investigators with an ASTCT New Investigator Awards.
  • Hosted a spotlight session at the 2025 Tandem Meetings to highlight research updates of past awardees.
Committee on Cellular Therapy
  • The Committee has been working to finalize three manuscripts that will be published in Transplantation and Cellular Therapy in the beginning of 2026:
    • “Chimeric Antigen receptor T-Cell Therapy in Autoimmune Disorder: An Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy”
    • “ASTCT Consensus Guidelines on Biomarker Testing During CAR T-cell Therapy”
    • “ASTCT Consensus Grading for Toxicities After Immune Effector Cell Therapy”
  • The Committee has also collaborated with the Society for Immunotherapy of Cancer (SITC) to hold a Solid Tumor Summit that aimed to address biological, operational and regulatory hurdles as CAR-T expands to solid tumors. The following manuscript will be available in the beginning of 2026:
    • “Advancing Cell Therapies for Solid Tumors: A Pathway to Overcome Biological, Operational, and Regulatory Hurdles”
  • The Committee has submitted two comment letters regarding recent draft guidance from the FDA on the following topics:
    • “Innovative Designs for Clinical Trials of Cellular and Gene Therapy Products in Small Populations: Draft Guidance for Industry”
    • “Post approval Methods to Capture Safety and Efficacy Data for Cell and Gene Therapy Products: Draft Guidance for Industry”
Committee on Diversity and Inclusion
  • Hosted a Diversity and Inclusion Reception at the 2025 Tandem Meetings.
  • Led a study section to award a young investigator for the Under-represented Minority (URM) New Investigator Award (NIA).
  • Collaborated with ASH to award the ASTCT-ASH Hematology Inclusion Pathway Award.
Committee on Education and Content
Committee on Education:
  • The Committee on Education had multiple accomplishments in 2025, including the creation of a Spotlight Session for the 2026 Tandem Meetings and a successful collaboration with Johnson & Johnson and Legend on a CAR-T Webinar Series.
  • Created a new structure for committee and SIG hosted webinars to kick off in 2026.
Committee on Content:
  • In collaboration with the Committee on Content, ASTCT Talks delivered 19 podcast episodes exploring diverse topics in hematopoietic cell transplantation.
  • Published infographic highlighting CAR T research, based on expertise from Tandem Meetings presenters and notes from Committee on Content experts.
In 2026, the Education and Content Committee will combine to further align content strategy and continue to meet the educational needs of ASTCT members.
Committee on Gene Therapy
  • The Committee on Gene Therapy originated as a task force charged with identifying recommendations for ASTCT’s future strategic focus. With its work proving essential to the organization’s direction, it has now transitioned into a standing committee.
Committee on Government Relations
  • Attended White House Forum on Cell and Gene Therapies in January 2025.
  • Hosted the 2025 Hill Day, which brought 30+ ASTCT members from across the country to Washington, D.C. to meet with close to 40 Congressional offices to advocate for ASTCT and the patients that we serve.
  • Co-hosted a Congressional Hill briefing on the importance of access to CAR T therapies with NMDP and the Cord Blood Association.
  • Relaunched ASTCT’s Advocacy webpage to provide members and the public with more information on ASTCT’s advocacy program.
Committee on Informatics
  • Contributed to the creation of ten sessions for the 2025 Tandem Meetings, including two keynote sessions and multiple case studies.
Committee on International Affairs
  • Oversaw applications for the 4th annual ASTCT International Trainee Observership Program, which allows a trainee from a resource constrained country to observe HCT/CT practice in the United States then travel to the Tandem Meetings.
  • Executed the 6th International Workshop that highlighted opportunities and challenges for CAR-T cell therapy worldwide by global experts.
  • Hosted the annual International Council Meeting to bring together key leaders from international organizations to discuss opportunities for collaboration.
  • Held a 2-part webinar on acute and chronic GVHD for members of the Pakistan Blood and Marrow Transplant.
Committee on Payer Relations
  • Hosted a panel at the 2025 Tandem Meetings, “Navigating the Outliers.”
  • Held Two Payer Engagement Meetings that convened close to 20 payers from across the country.
  • Oversaw comprehensive revision to the RFI forms with CIBMTR data definitions.
  • Hosted two webinars
    • FACT Accreditation in the Community
    • RFI and Its Role in the Payer-Provider Relationship
Committee on Practice Guidelines
  • Collaborated with the Infectious Diseases SIG to publish four guidelines on Rare Molds, HHV6, Parainfluenza and Human Metapneumovirus Infections and CMV.
  • Published three additional guidelines on CLL, CHL and Nutritional Care for Adult HCT Patients.
  • Hosted their annual Spotlight Session at the 2025 Tandem Meetings highlighting recently published manuscripts.
Committee on Scientific Affairs
  • Hosted a Spotlight Session and a Scientific Workshop at the 2025 Tandem Meetings.
  • Contributed to the planning of the 2026 Tandem Meetings through the Scientific Organizing Committee and will host two Spotlight Sessions and a Scientific Workshop in 2026.
  • Contributed to the planning and development of the Joint ASTCT+EBMT Basic and Translational Scientific Meeting and the ASTCT Translational Science Training Course.
Committee on Quality Outcomes
  • Committee held a session within the Admin Track at the 2025 Tandem Meetings, titled “Bridging the Gap: Enhancing Long-Term Outcomes through Comprehensive Follow-Up in Transplant and Cellular Therapy Patients.”
Committee on Trainees and Junior Faculty
  • Hosted a 2-part webinar series to highlight the clinical, logistics and administrative challenges behind transplantation and CAR-T across the world.
  • Working to collaborate on developing an onboarding guide for trainees during their fellowship that highlights critical resources and education in the HCT/CT space.

Special Interest Group (SIG) Accomplishments

Administrative Directors SIG
  • Held the 2025 Tandem Meetings Administrative Directors track.
  • Conducted a comprehensive HCT Staffing Survey and released benchmark results to participating institutions.
  • The Quality Subcommittee developed a draft cell therapy lab checklist including quality, IT security and operational aspects of onboarding new therapy products.
Advanced Practice Provider SIG
  • Held the 2025 Tandem Meetings APP Track that saw approximately 375 attendees.
  • Hosted the 2025 Clinical Education Conference in Dallas, TX, that saw 148 attendees.
  • Hosted three webinars on gynecologic issues in pediatric oncology, strategies for difficult conversations and care considerations for LGBTQI+ populations.
  • The Professional Development Subcommittee hosted a four-part webinar series for APPs.
Aging SIG
  • Published three guidelines in Transplantation and Cellular Therapy.
    • “U.S. Geriatric Assessment Practices”
    • “Assessing Physical Function”
    • “Assessing Cognitive Function”
  • Presented the Spotlight Session at the 2025 Tandem Meetings, “Survivorship and Long-term Follow up in the Most Vulnerable Age Populations” in conjunction with the Survivorship SIG.
  • Working on a retrospective multicenter study looking at the cardiac toxicity of PTCy in older adults, with an exploratory analysis looking at PTCy dose reduction.
Biobehavioral Research SIG
  • Produced two articles in Transplantation and Cellular Therapy:
    • “Assessing Physical Function in Transplantation and CAR-T Recipients”
    • “Assessing Cognitive Function in Transplantation and Chimeric Antigen Receptor T Cell Therapy Recipients”
  • Hosted a webinar in October to promote networking using virtual “Speed Dating.”
  • “Enhancing Rigor and Reproducibility in BBR Research” now being written for publication in spring 2026.
Cord Blood SIG
  • Hosted a Spotlight Session at the 2025 Tandem Meetings, “New Frontiers in Cord Blood Therapies: Current Perspectives and Future Directions.”
  • Hosted a webinar on the cord blood transplant in hematological malignancies.
  • Collaborated on ASTCT Talks podcast episode, “Cord Blood Transplantation: Past, Present and Future Innovations.”
HCT Value and Health Economics SIG
  • The Steering Committee developed a 90-minute session within the Administrative Directors Track at the Tandem Meetings, which highlighted system capacity opportunities in cell therapies.
Nursing SIG
  • The SIG Steering Committee curated a robust track for the 2025 Tandem Meeting, showcasing top science and best practices in the field of HCT, along with choosing one highly esteemed volunteer to receive the Nursing travel grant.
Palliative and Supportive Care SIG
  • Published “What Do Pediatric Transplant Physicians Think About Palliative Care? Results From a National Survey Study,” in Bone Marrow Transplant.
  • Hosted a webinar, “Palliative Care SIG Best Posters at Tandem.”
  • SIG Chair Christina Ullrich presented “Palliative Care Integration” at ASTCT’s Clinical Education Conference to over 150 attendees, primarily APPS and nurses.
Pharmacy SIG
  • SIG members participated in ASTCT Talks and Pharmacy Times podcasts.
  • Held the 2025 Tandem Meetings Pharmacy Track that saw approximately 250 attendees.
  • Pharmacy SIG Fundamentals Subcommittee hosted another successful Fundamentals of HCT Training Course that saw 442 attendees and representation from over 31 countries outside of the United States. The group also published the 2025 Fundamentals eBook, which included a new chapter on Special Populations: Geriatrics.
  • Hosted 13 webinars.
Social Work SIG
  • SIG held a session within the Nursing Track at the 2025 Tandem Meetings titled, “Patient and Family Dynamics: A Case Study Approach to Difficult Situations.”
  • SIG held a session within the Admin Track at the 2025 Tandem Meetings titled, “Reimagining Caregiving Together.”
Survivorship SIG
  • Presented the Spotlight Session at the 2025 Tandem Meetings, “Survivorship and Long-term Follow up in the Most Vulnerable Age Populations” in conjunction with the Aging SIG.
  • Published four articles in Transplantation and Cellular Therapy:
    • “Assessing Quality of Life and Symptoms in Transplantation and CAR-T Recipients”
    • “Assessing Cognitive Function in Transplantation and Chimeric Antigen Receptor T Cell Therapy Recipients”
    • “Assessing Physical Function in Transplantation and CAR-T Recipients”
    • “Assessing Social Determinants of Health in Transplantation and CAR-T Recipients”
  • Hosted three webinars.
Transplant Infectious Diseases SIG
  • Presented a successful one-day track session at the 2025 Tandem Meetings with 405 attendees.
  • Published three articles in Transplantation and Cellular Therapy:
    • “Updated Cytomegalovirus Guidelines in HCT/CT”
    • “Management and Prevention of Non-Aspergillus Molds in HCT”
    • “Management of Human Herpesvirus 6B After HCT/CAR T”
  • Collaborative Research Framework within the ID SIG commenced activity in November 2025.
  • Worked with ASH to jointly publish a Measles Vaccine FAQ.
  • Published a Healio blog post on preparing transplant, cellular therapy recipients for the respiratory viral season.
  • Hosted two webinars.

2025 Tandem Meetings Highlights

Welcomed more than 5,000 attendees, a record number for the past few years.
Hosted ten educational tracks.
Received more than 1,180 abstract submissions.
Held 48 presentations in the scientific plenary and concurrent sessions.

Awards

ASTCT honors outstanding achievements in the hematopoietic cell transplantation and cellular therapy fields. This year we recognize individuals that have shown significant career impact in research and service. Congratulations to the 2025 award winners!

Education Offerings

Members can access archived webinars, publications by ASTCT and other educational content in the ASTCT Learning Center. Since its launch in June of 2020, the Learning Center has continued to grow and now offers more than 139 different education products, with 7,768 unique registrations and purchases in 2025 alone. It will continue to flourish and expand with the education portfolio of ASTCT in the coming years.

Most Popular Webinars in 2025

Measles Outbreaks and Implications for HCT and CAR T-Cell Therapy Patients
ASTCT HCT Coverage & Reimbursement Guide Webinar
Management and Prevention of Non-Aspergillus Molds in HCT Recipients
The Best of CAR T at the 2025 Tandem Meetings
FACT Accreditation in the Community Provider Setting

Advocacy

ASTCT proudly advocates on behalf of our members and patients. We ensure patient access to life-saving therapies by advocating at the federal and state levels.

ASTCT has continued to engage in advocacy efforts throughout the year.

Hosted ASTCT’s 2026 Hill Day to increase awareness of ASTCT and the patients our members serve, and advocate for legislation that would increase access and promote advancement in cellular and transplantation therapies. Our 2025 Hill Day included 34 ASTCT members who met with 43 House and Senate offices in one day.

Co-hosted a Congressional Hill briefing on the importance of access to CAR T therapies with NMDP and the Cord Blood Association.

Held Two Payer Engagement Meetings that convened close to 20 payers from across the country.

Oversaw comprehensive revision to the RFI forms with CIBMTR data definitions.

Attended White House Forum on Cell and Gene Therapies in January 2025.

 

ASTCT’s Hill Day Asks for 2025:

Protect and Support the National Institutes of Health (NIH) and its Institutions
Co-Sponsor S.752/H.R. 1509: the Accelerating Kids Access to Care Act
Reauthorize the C.W. Bill Young Cell Transplantation Program
 

Where We’re Headed Next — 2026-2028 Strategic Plan

StrategicPlan.png
Influence

Identify and define key audiences in the HCT and related cellular therapies.

Communicate ASTCT’s value and advocate on its behalf to those audiences.

Engage target audiences to join, partner with and remain active in ASTCT.

Innovation

Expand and enhance ASTCT’s education offerings in HCT and related cellular therapies.

Align partnerships with professional societies to advance ASTCT’s mission and strategic priorities.

Growth

Grow membership through data-driven recruitment and retention strategies.

Evaluate and optimize the Tandem Meetings success and impact.

Diversify revenue and funding streams.

Financial Report

ASTCT FY2025 Statement of Financial Position (Unaudited)

Cash & Investments
15,040,558
Other Assets
781,878
Total Assets
15,822,435
Accounts Payable
513,821
Deferred Revenue
3,485,707
Total Liabilities
3,999,529
Net Assets
11,822,907
Total Liabilities and Net Assets
15,822,435

ASTCT FY2025 Statement of Activities (Unaudited)

Total Operating Revenue
8,509,187
Total Operating Expense
7,755,249
Net Operating Income
753,937
Investment Activity
1,913,040
Net Income
2,666,977

2025 Corporate Council

Thank you to our 2025 corporate council members for their generosity and support.

 

President's Circle

Thank You to Our President's Circle

 

 
sanofi
Platinum

Thank You to Our Platinum Members

bristol_myers_squibb johnson_johnson kite
merck novartis sobi takeda
Silver

Thank You to Our Silver Members

AbbVie Alexion Autolus CareDx Gamida Cell Genetix Biotherapeutics Incyte Iovance Biotherapeutics Jazz Pharmaceuticals Legend Biotech USA Inc. McKesson Pharmaceutical Solutions and Services Medexus Pharmaceuticals, Inc. Mesoblast, Inc. Pfizer Takeda Syndax US WorldMeds Vertex

Emerging

Thank You to Our Emerging Members

Arcellx Beam Therapeutics Caribou Biosciences CSL Miltenyi Biomedicine Inc. Orca Bio Pierre Fabre Secura Bio

ASTCT is dedicated to advancing hematopoietic cell transplantation (HCT) and related cellular and gene therapies through research, education and clinical practice.